A new study reveals that a common malaria and arthritis drug, hydroxychloroquine, is an effective tool in combating Covid-19. The study was undertaken by the Henry Ford Health System between March and May involving 2,541 patients.
While 26.4% of those who did not receive hydroxychloroquine died, only 13% of those who did get the drug died.
The study was headlined, “Treatment with hydroxychloroquine cut death rate significantly in COVID-19 patients, Henry Ford Health System study shows.”
The study published in the International Journal of Infectious Diseases said, “all patients in the study were 18 or over with a median age of 64 years; 51% were men and 56% African American.”
The hospital attributed its high success rate to giving people the drug within 48 hours of admittance to their hospitals.
Speaking on behalf of the hospital, Dr. Marcus Zervos said:
“The findings have been highly analyzed and peer-reviewed.”
“We attribute our findings that differ from other studies to early treatment, and part of a combination of interventions that were done in supportive care of patients, including careful cardiac monitoring. Our dosing also differed from other studies not showing a benefit of the drug. And other studies are either not peer reviewed, have limited numbers of patients, different patient populations or other differences from our patients.”
However, the drug became high politicized once US President Donald Trump recommended hydroxychloroquine in the treatment of COVID. One politician even threatened to charge the President with crimes against humanity for recommending the drug:
I can’t take it anymore. I’ve been to The Hague. I’m making a referral for crimes against humanity tomorrow. Today’s press conference was the last straw. I know the need for a prosecution referral when I see one. https://t.co/XQin24gqY4
— Rep. Tavia Galonski (@RepGalonski) April 6, 2020
And a study in the peer reviewed journal The Lancet claiming that hydroxychloroquine treatment for COVID actually made people worse was quickly withdrawn after several researchers questioned the data. READ: The Lancet’s Hydroxychloroquine Study Is Retracted by Its Authors